Camostat mesylate

• CAT Number: I004239
• CAS Number: 59721-29-8
• Molecular Formula: C20H22N4O5 • CH3SO3H
• Molecular Weight: 494.50
• Purity: ≥95%
• Synonyms: Foipan;FOY 305
• Target: Trypsin-like protease
• Solubility: 10 mM in DMSO, 10 mM in H2O
• Storage: 3 years -20C powder
• IUPAC Name: [4-[2-[2-(dimethylamino)-2-oxoethoxy]-2-oxoethyl]phenyl] 4-(diaminomethylideneamino)benzoate;methanesulfonic acid
• InChI: InChI=1S/C20H22N4O5.CH4O3S/c1-24(2)17(25)12-28-18(26)11-13-3-9-16(10-4-13)29-19(27)14-5-7-15(8-6-14)23-20(21)22;1-5(2,3)4/h3-10H,11-12H2,1-2H3,(H4,21,22,23);1H3,(H,2,3,4)
• InChIKey: FSEKIHNIDBATFG-UHFFFAOYSA-N
• SMILES: CN(C)C(=O)COC(=O)CC1=CC=C(C=C1)OC(=O)C2=CC=C(C=C2)N=C(N)N.CS(=O)(=O)O

Camostat mesylate（Cat No.:I004239）is a serine protease inhibitor commonly used in the treatment of pancreatitis and reflux esophagitis. It works by inhibiting enzymes like trypsin and kallikrein, reducing inflammation and tissue damage. Recently, camostat mesylate has gained attention for its potential antiviral properties, particularly in inhibiting the transmembrane protease serine 2 (TMPRSS2), which is involved in viral entry, including that of SARS-CoV-2. Its ability to block viral replication has made it a subject of interest in COVID-19 research. Camostat mesylate continues to be studied for various therapeutic applications.

Reference

[1]. Okuno, M., et al., Prevention of rat hepatic fibrosis by the protease inhibitor, camostat mesilate, via reduced generation of active TGF-beta. Gastroenterology, 2001. 120(7): p. 1784-800.
[2]. Yamamoto, A., et al., Effects of various protease inhibitors on the intestinal absorption and degradation of insulin in rats. Pharm Res, 1994. 11(10): p. 1496-500.
[3]. Gibo, J., et al., Camostat mesilate attenuates pancreatic fibrosis via inhibition of monocytes and pancreatic stellate cells activity. Lab Invest, 2005. 85(1): p. 75-89.